Potential new prognostic microRNA biomarker after cardiac arrest

The team of the Cardiovascular Research Unit team of the Luxembourg Institute of Health (LIH) has published an original investigation in JAMA Cardiology reporting a potential new prognostic biomarker after cardiac arrest.

Cardiac arrest is a grave condition with high risk of death with severe neurological sequelae. The prediction of outcome after resuscitation from cardiac arrest can allow tailoring healthcare to the individual patient, optimizing costly resources in intensive care units to patients who would mostly benefit. However, current prediction tools have great limitations. This study shows that microRNAs can be used to improve outcome prediction after cardiac arrest. These small RNA molecules are found circulating in the bloodstream, thus are easily obtained from patients. The finding that the brain-enriched microRNA 124 circulating in blood has the ability to be used as a prognostic tool represents a major step forward towards personalized medicine.

This work is the result of a long-standing collaboration between the Cardiovascular Research Unit of LIH, the Department of Anaesthesia and Intensive Care of the Centre Hospitalier de Luxembourg, and the members of the international multicentre randomized clinical trial TTM (Target Temperature Management). All collaborators are members of the Cardiolinc network, coordinated by the Cardiovascular Research Unit. The study was supported by the Ministry of Higher Education and Research, and the Luxembourg National Research Fund (FNR).

Read this news on the LIH website and the interview with Dr Yvan Devaux featuring the publication on MedicalResearch.com.